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R
e s e a r c h i n c o n t e x t 3 5 Evidence before this study 3 6 Many cross-sectional prevalence studies have compared the characteristics of patients 3 7 with persistent airflow limitation but no prior diagnosis of COPD ('undiagnosed') to 3 8 those with persistent airflow limitation and a diagnosis of COPD ('diagnosed'). We 3 9 searched MEDLINE and EMBASE for observational studies published in English between January 1, 1980 and April 11, 2017 that assessed diagnosis status among adult 4 1 patients with spirometrically defined persistent airflow limitation. We used search terms Search strategy and selection criteria 1 0 7
We conducted a systematic review and meta-analysis to compare patient characteristics,
risk factors, and symptoms in diagnosed and undiagnosed patients. We searched 1 0 9
MEDLINE and EMBASE using the Ovid interface for eligible articles. The search using appropriate vocabulary terms. We included longitudinal or cross-sectional studies analysis of individual data. We did not include conference abstracts unless they met the inclusion criteria and provided the required information, and we did not assess grey 1 1 5 literature. We extracted summary data from the eligible articles and contacted the authors 1 1 6 to obtain additional information when required (one author group provided us with 1 1 7 additional information). Title and abstract screening were initially performed, followed 1 1 8 by full-text analysis to determine article eligibility. We extracted data using a customized 1 1 9 Excel spreadsheet after the eligible articles had been compiled. KJ initially performed the 1 3 7 bronchodilator during spirometry. Study subjects who had airflow limitation and also a 1 3 8 prior diagnosis of COPD or an obstructive lung disease (emphysema, chronic bronchitis,
asthma) from a health-care professional were considered to have 'diagnosed' COPD, diseases were excluded. We included studies that sampled patients from any population 1 4 3 or health-care setting.
Given the exploratory nature of the observational studies included in this review, we used
a broad definition of risk factors that included any observable factor that could be 1 4 6 associated with the probability of having received a diagnosis of COPD. Risk factors 1 4 7 included patient-reported respiratory symptoms (cough, wheeze, phlegm, dyspnoea), sex,
age, current smoking status, smoking history (pack-years), and disease severity classified relationship of interest was the association between these risk factors and the probability
of having 'diagnosed' COPD among patients with persistent airflow limitation.
We extracted summary data from each eligible article, which included study 1 5 3 characteristics, the definition of persistent airflow limitation that was employed in each of 1 5 4 the studies, the method of COPD diagnosis, and sample size. We also extracted the 1 5 5 proportion or mean of risk factors between the diagnosed and undiagnosed groups, as 1 5 6 well as the odds ratios (ORs) and their confidence intervals in studies that used regression 1 5 7 modelling to assess the independent impact of the risk factors on diagnosis status. The
protocol for this study is registered on the PROSPERO register of systematic reviews 1 5 9 (CRD42017058235). Data analysis
We used data extracted from articles measuring categorical data to generate ORs and standard errors for the association between risk factors and the probability of having 1 6 3 received a diagnosis of COPD. In articles assessing continuous data, we calculated the undiagnosed patients. We pooled the ORs or MDs from individual studies using the 1 6 6 inverse variance method implemented with the 'meta' package 11 in R Statistical
Software 12 (version 3.3.3). We used fixed-effects models when estimates from only two 1 6 8 studies were being pooled, or if the null hypothesis that all studies evaluated the same effect was not rejected (at 0·05 significance level) using Cochran's Q statistic. Otherwise, we used random-effects models. We quantified heterogeneity between studies largest sample size. We conducted a sensitivity analysis to determine the association 1 7 6 between the risk factors and COPD diagnosis only among population-based studies 1 7 7 (those based on random sampling of the general population as opposed to convenience 1 7 8 sampling). Role of the funding source
The funder of this study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author and co-authors had full 1 8 2 access to the data in the study and take responsibility for the integrity of the data, the
accuracy of the analyses, and the decision to submit for publication. The search resulted in 1,857 references after excluding duplicates. 1,788 references were 1 8 6 excluded by screening their titles and abstracts, and 69 remained for full text review to 1 8 7 determine eligibility. A total of 18 articles met the inclusion criteria following the 1 8 8 screening process, but only 16 articles were included in quantitative synthesis ( Figure 1 ).
The overall agreement between reviewers was high (90%). A summary of the 18 eligible articles is presented in Table 1 . However, two eligible articles were excluded from the meta-analysis because they were missing the necessary
information, 18 or did not measure any risk factors in common with other studies. 19 The majority of the 18 eligible articles were cross-sectional (n=16), and were population- based (n=10). Other studies sampled patients from primary care clinics (n=4), 1 9 6 hospitalized patients (n=3), or participants in a smoking cessation program (n=1). Studies
originated from Latin America (n=6), Europe (n=6), Canada (n=2), and Asia (n=2). Data
from the Epidemiologic Study of COPD in Spain (EPI-SCAN), 4, 20, 21 PLATINO, and the
Burden of Obstructive Lung Disease (BOLD), 4, 22 were used in three, four, and two from health-care settings).
The quality of the 18 eligible articles was variable. Half of the studies were assigned a 2 0 8 quality rating of 'good', seven studies were assigned a rating of 'fair', and two studies 2 0 9
were deemed poor in quality. Studies that were not assigned a 'good' quality rating
generally had a primary study focus that was not our question of interest. For example,
comparing the characteristics of diagnosed and undiagnosed patients was only reported
tangentially in five studies, and disease severity was the only factor that was compared
between the undiagnosed and diagnosed groups in three of the studies. The use of regression modelling to examine the independent impact of risk factors on the likelihood
of receiving a COPD diagnosis was uncommon (performed in only seven studies), and in
variability between the three studies measuring this risk factor was particularly high (I 2 2 3 9 77·9%). results (Appendix, Figure A2 ); however, cough was marginally associated with diagnosis
status in this analysis (OR 1·65, 95% CI 1·02-2·66). Similarly, patients with 'diagnosed' COPD (fixed ratio definition) were more impaired by -12·85%, 95% CI -15·26% to -10·44%, 4 studies) than undiagnosed patients. Patients
with 'diagnosed' COPD also had a slightly greater smoking history (pack-years MD 8·39,
95% CI 0·68-16·44, 4 studies); however there was high variability between the study Adjusted analysis 2 5 6 Articles using regression modelling to assess the independent impact of risk factors on
COPD diagnosis ('adjusted analysis') were pooled by risk factor type, and the results are presented in Figure 4 for the fixed ratio definition of persistent airflow limitation (5
articles), and Figure 5 for the LLN definition (2 articles with 5 datasets). The effect sizes a weak independent association with the diagnosis of COPD (OR 1·16, 95% CI 1·00-
1·35, 2 studies) using the fixed ratio definition. The presence of wheezing (OR 1·20, 95% severe or very severe (reference GOLD grades III-IV). Sex and the presence of cough did number of studies were small and heterogeneity in the effect estimates between studies
was very high (I 2 >70.0% for all risk factors except sex).
Three risk factors were pooled in our assessment of studies using adjusted analysis based
on the LLN definition of persistent airflow limitation. This analysis indicated a more 2 7 4 strongly positive association between the presence of phlegm and being diagnosed with COPD (OR 1·71, 95% CI 1·15-2·56), although there was heterogeneity between datasets (I 2 75·2%). Patient sex and the presence of cough had no independent effect. The presence of respiratory symptoms and GOLD 3 or 4 disease severity was strongly
associated with a prior diagnosis of COPD among individuals with persistent airflow
limitation on spirometry. These findings were relatively consistent across analysis was the most important characteristic of diagnosed patients in two out of three pooled 2 8 3 analyses in which spirometry was performed. In particular, patients with mild or moderate COPD (as measured by GOLD grades) were 78% less likely to have received a 2 8 5 diagnosis than patients with severe or very severe COPD in the unadjusted analysis 2 8 6 (based on contingency tables), and mean percent predicted FEV 1 was 13% lower in 2 8 7 diagnosed than undiagnosed patients. Disease severity was also the only risk factor that
was associated with a diagnosis in both the unadjusted and adjusted (based on regression
modelling) analyses. In the adjusted analysis, patients with moderate COPD were 29% less likely to have received a diagnosis than patients with severe or very severe COPD. Respiratory symptoms were another group of risk factors that were correlated with a
COPD diagnosis. Among respiratory symptoms, the presence of dyspnoea was the most 'diagnosed' COPD scored 0·52 points higher on the mMRC dyspnoea scale. However,
there was only one study 25 in which the mean score on the mMRC scale could have been 2 9 6 used to distinguish undiagnosed from diagnosed patients using commonly accepted Following dyspnoea, the presence of wheeze, and phlegm was also strongly associated 2 9 9 with 'diagnosed' COPD in the unadjusted analysis. However, in the adjusted analysis, (discussed in detail below), our findings suggest a strong association between the presence of dyspnoea, phlegm, or wheeze and a COPD diagnosis. In addition to patients
with respiratory symptoms being more likely to seek care, current guidelines now
consider the presence of symptoms as part of the criteria for diagnosing COPD among
patients with persistent airflow limitation 1 .
0 9
Patient characteristics such as sex and age were not associated with an increased
likelihood of having received a diagnosis in any of the pooled analyses. There was some
indication that patients with 'diagnosed' COPD had a greater pack-year smoking history,
although current smoking status and smoking history were not statistically significant
when they were assessed as the presence of former smoking and never smoking. The effects of risk factors on the likelihood of being diagnosed were weaker in the
adjusted analyses than in the unadjusted analyses. The adjusted analyses were based on
pooled coefficients from regression modelling. Although the inclusion of covariates is
expected to reduce the effects sizes compared to odds ratios derived from contingency tables (as in the unadjusted analysis), one study in the adjusted analysis 23 had unusual results that received disproportionate weighting. In contrast to all other studies in this
review, Herrera et al. 23 found that respiratory symptoms were not associated with the likelihood of having received a diagnosis of COPD. In the adjusted analysis, these results
were pooled with one other study 17 , which found that the presence of respiratory between studies may be due to differences in the population that was sampled (primary observed smaller differences between undiagnosed and diagnosed patients because they
sampled from a subset of patients that were prompted to seek care because of a symptom burden.
Our systematic review has several strengths. First, we used data from a total of 16 articles
in the meta-analysis, and these articles were mostly population-based studies that scored
high in quality. Second, there were a robust number of studies for many risk factors;
patient sex was assessed in 10 studies in total, followed by disease severity in 9 studies, 3 3 3 and respiratory symptoms and smoking history in 8 studies each. The methods used to 3 3 4 measure disease severity, respiratory symptoms, and smoking history were relatively consistent across studies, which facilitated pooling of their findings. Lastly, we conducted several pooled analyses to assess the sensitivity of our findings to alternate definitions of COPD (fixed ratio and LLN) and analysis methods (unadjusted and adjusted analyses).
8
Except for one study, 23 our findings were consistent.
However, our systematic review also has several limitations. First, half of the pooled
samples were based on data from three large prevalence studies (EPI-SCAN, PLATINO, findings that vary across settings. Second, although the total number of studies for each 3 4 4 risk factor was robust, the number of studies assessing each risk factor within pooled analyses tended to be small. This was partly because separate articles using the same other respiratory symptoms in the pooled analyses were measured as binary variables (either present or absent). Given our finding that symptoms are characteristic of a COPD
diagnosis, a more nuanced assessment of their severity might result in an even greater 3 5 2 ability to distinguish between undiagnosed and diagnosed patients. In addition, because 3 5 3 respiratory symptoms were self-reported in all studies, reporting bias might have 3 5 4 exaggerated the difference in symptoms between the undiagnosed and diagnosed groups.
The findings from this systematic review have important implications for research and
policy around COPD diagnosis, for example, in estimating the return on investment in 3 5 7 screening and case detection strategies for COPD. The true burden of COPD is the sum 3 5 8 of the disease burden in diagnosed and undiagnosed patients, and our results indicate that 3 5 9 undiagnosed patients generally have milder disease and therefore a lower disease burden.
On one hand, this indicates that strategies aiming to reduce the underdiagnosis problem are unlikely to result in immediate and dramatic improvements in patient-related
outcomes such as symptom burden. On the other hand, the gap in disease severity and
symptom burden between diagnosed and undiagnosed patients indicates a delay in COPD 3 6 4 diagnosis among patients that have already developed symptoms. Given the potential for 3 6 5 disease modification at early stages of COPD, reducing this delay could be associated 3 6 6 with substantial improvement in long-term patient outcomes and a reduction in mortality 3 6 7 and costs. Acknowledgements: This study was funded by the Canadian Institutes of Health
Research (application number 142238). 
